Casebia combines CRISPR/Cas9 expertise and technology from CRISPR Therapeutics with access to deep disease-state knowledge and protein engineering capabilities from Bayer. Our aim: to transform the lives of patients and families affected by genetic disease.
Congratulations to CRISPR developer, Emmanuelle Charpentier and her colleagues for winning this year’s Kavli Prize in #Nanoscience. “for the invention of CRISPR-Cas9, a precise nanotool for editing DNA, causing a revolution in biology, agriculture, and medicine” @KavliPrize
Casebia is pleased to announce our new Head of Regulatory Affairs, Amy Jennings. “Amy brings a depth of experience that we believe will be invaluable in formulating our product development and global regulatory strategies,” -Jim Burns, Ph.D., Casebia’s CEO https://t.co/XJNlGUaRhl